Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

BACKGROUND: Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC). Study COU-AA-302 evaluated abiraterone acetate plus prednisone versus prednisone alone in mildly symptomatic or asympto...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur Urol
Hlavní autoři: Rathkopf, Dana E., Smith, Matthew R., de Bono, Johann S., Logothetis, Christopher J., Shore, Neal D., de Souza, Paul, Fizazi, Karim, Mulders, Peter F.A., Mainwaring, Paul, Hainsworth, John D., Beer, Tomasz M., North, Scott, Fradet, Yves, Van Poppel, Hendrik, Carles, Joan, Flaig, Thomas W., Efstathiou, Eleni, Yu, Evan Y., Higano, Celestia S., Taplin, Mary-Ellen, Griffin, Thomas W., Todd, Mary, Yu, Margaret, Park, Youn C., Kheoh, Thian, Small, Eric J., Scher, Howard I., Molina, Arturo, Ryan, Charles J., Saad, Fred
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4418928/
https://ncbi.nlm.nih.gov/pubmed/24647231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2014.02.056
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky